Batilol

Batilol

SCHEMBL940982

CCCCCCCCCCCCCCCCCCOCC(O)CO.CCOCC

nearest known ligand 0.89

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
USP2 O75604 1/20 0.89
HTT P42858 2/20 0.62
LPAR5 Q9H1C0 4/20 0.54
PLA2G2C Q5R387 1/20 0.52
MEN1 O00255 2/20 0.49
KMT2A Q03164 2/20 0.49
SPHK1 Q9NYA1 1/20 0.49
KDM4E B2RXH2 1/20 0.49
DUSP3 P51452 1/20 0.49
LMNA P02545 1/20 0.49
THRB P10828 1/20 0.47
MAPT P10636 1/20 0.47
CYP1A2 P05177 1/20 0.46
CYP3A4 P08684 1/20 0.46
CYP2C19 P33261 1/20 0.46
LPAR1 Q92633 5/20 0.42
LPAR3 Q9UBY5 5/20 0.42
LPAR2 Q9HBW0 4/20 0.42
LPAR6 P43657 3/20 0.42
LPAR4 Q99677 3/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ether SCHEMBL6805057 1.00 USP2 (0.89) USP2HTTLPAR5PLA2G2CMEN1
Ether SCHEMBL2015031 1.00 USP2 (0.89) USP2HTTLPAR5PLA2G2CMEN1
Ether SCHEMBL93806 1.00 USP2 (0.89) USP2HTTLPAR5PLA2G2CMEN1
Ether SCHEMBL8501744 1.00 USP2 (0.89) USP2HTTLPAR5PLA2G2CMEN1
Ether SCHEMBL6428915 1.00 USP2 (0.89) USP2HTTLPAR5PLA2G2CMEN1
Ether SCHEMBL2390477 1.00 USP2 (0.89) USP2HTTLPAR5PLA2G2CMEN1
Ether SCHEMBL8502252 1.00 USP2 (0.89) USP2HTTLPAR5PLA2G2CMEN1
Ether SCHEMBL3811088 1.00 USP2 (0.89) USP2HTTLPAR5PLA2G2CMEN1
Ether SCHEMBL8501725 0.98 USP2 (0.85) USP2HTTLPAR5PLA2G2CMEN1
SCHEMBL24835077 0.94 USP2 (1.00) USP2HTTLPAR5PLA2G2CMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2011084430-A1 COMPOSITION AND METHOD FOR REDUCING FRICTION IN INTERNAL COMBUSTION ENGINES BP CORPORATION NORTH AMERICA INC. (US) 2011-07-14 WO claimed
US-20110146144-A1 Composition and Method for Reducing Friction in Internal Combustion Engines BP CORPORATION NORTH AMERICA INC. (US) 2011-06-23 US claimed
US-20040208783-A1 Process for the chemical and thermal disinfection AIR LIQUIDE SANTE (INTERNATIONAL ) (FR) 2004-10-21 US claimed
EP-1468606-A1 Process for the chemical and thermal disinfection Air Liquide Santé (International) (FR) 2004-10-20 EP claimed
WO-2024058214-A1 SOLID EMULSIFIER FOR OIL-IN-WATER TYPE EMULSION, PRODUCTION METHOD OF OIL-IN-WATER TYPE EMULSION, OIL-IN-WATER TYPE EMULSION AND COSMETIC COMPOSITION 三洋化成工業株式会社 2024-03-21 WO disclosed
US-20220000758-A1 COSMETIC SHISEIDO COMPANY, LTD. (JP) 2022-01-06 US disclosed
US-20220001443-A1 POWDER DISPERSION COMPOSITION AND DISPERSING METHOD THEREOF SHISEIDO COMPANY, LTD. (JP) 2022-01-06 US disclosed
EP-3881820-A1 POWDER DISPERSION COMPOSITION AND DISPERSING METHOD THEREOF Shiseido Company, Ltd. (JP) 2021-09-22 EP disclosed
EP-3881899-A1 COSMETIC Shiseido Company, Ltd. (JP) 2021-09-22 EP disclosed
EP-2292208-B1 EXTERNAL PREPARATION FOR SKIN SHISEIDO CO LTD (JP) 2017-07-19 EP disclosed
US-20140120051-A1 Skin Cosmetic SHISEIDO COMPANY, LTD. (JP) 2014-05-01 US disclosed
US-8642023-B2 Skin cosmetic SHISEIDO COMPANY, LTD. (JP) 2014-02-04 US disclosed
US-6169114-B1 STORAGE STABILITY, THIOL COMPOUND IS ONE OR MORE TYPES OF CYSTEINE AND ITS DERIVATIVES, ZINC OXIDE HAVING A WATER REPELLANT TREATMENT ON ITS SURFACE, SHISEIDO COMPANY, LTD. (JP) 2001-01-02 US disclosed
EP-0976381-A1 DERMATOLOGIC PREPARATION SHISEIDO COMPANY LIMITED (JP) 2000-02-02 EP disclosed
EP-0941087-A1 TOPICAL FORMULATIONS CONTAINING AS A THERAPEUTIC ACTIVE AGENT FATTY ACIDS OR FATTY ALCOHOLS OR MONOGLYCERIDE DERIVATIVES THEREOF FOR TREATING OF MUCOSA INFECTIONS Thormar, Halldor (IS) 1999-09-15 EP disclosed
US-5849834-A W/O type emulsified composition and cosmetic SHISEIDO CO., LTD. (JP) 1998-12-15 US disclosed
US-5767158-A FOR BLEACHING SKIN SHISEIDO CO., LTD. (JP) 1998-06-16 US disclosed
WO-1998020872-A1 TOPICAL FORMULATIONS CONTAINING AS A THERAPEUTIC ACTIVE AGENT FATTY ACIDS OR FATTY ALCOHOLS OR MONOGLYCERIDE DERIVATIVES THEREOF FOR TREATING OF MUCOSA INFECTIONS THORMAR HALLDOR (IS) 1998-05-22 WO disclosed
EP-0795318-A2 A w/o cosmetic emulsion containing ethylcellulose SHISEIDO COMPANY LIMITED (JP) 1997-09-17 EP disclosed
EP-0728469-A2 An endermic liniment SHISEIDO COMPANY LIMITED (JP) 1996-08-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220000758-A1 COSMETIC CUTA, SQLE, FDFT1 USP2 3492/4885HTT 1706/4885LPAR5 1187/4885
US-20140120051-A1 Skin Cosmetic CUTA, SMC3, H1-0 USP2 411/4885HTT 2440/4885LPAR5 2137/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.